Purple Biotech (NASDAQ: PPBT) — Company Overview, News & Financial Data
Purple Biotech focuses on developing innovative cancer therapies that target treatment resistance and improve patient outcomes.

Purple Biotech
Purple Biotech (TLV:PPBT), (NASDAQ:PPBT) is a biotechnology company focused on advancing various cancer therapies that target the challenges of resistance to treatments. With a pipeline that includes development-stage drugs aimed at providing new options for cancer patients, Purple Biotech's projects predominantly revolve around creating innovative, targeted therapies. The company's objective is to improve patient outcomes by exploring pathways and mechanisms that can overcome tumor resistance and reduce side effects, making cancer treatments more effective and tolerable. Purple Biotech is solely listed on the NASDAQ stock exchange under the symbol PPBT, highlighting its commitment to research and development in the oncology sector.
Snapshot
Operations
Products and/or services of Purple Biotech
- NT219, a small molecule targeting treatment-resistant cancer pathways.
- CM24, a monoclonal antibody inhibiting CEACAM1 for various cancers.
- Research partnership for developing novel cancer therapies.
- Collaboration on drug discovery and development in oncology.
- Involvement in early-stage research on tumor microenvironment targeted therapies.
- Expertise in kinase inhibitor technology for cancer treatment.
Purple Biotech executive team
- Shai LankryChief Financial Officer
- Michael SchicklerHead of Clinical & Regulatory Affairs
Latest news about Purple Biotech
Purple Biotech shares preclinical data on T-Cell engager platform
United StatesPurple Biotech narrows Q1 net loss as cancer pipeline progresses
United StatesPurple Biotech shares gain on preclinical data for tri-specific antibody IM1240
United StatesPurple Biotech shifts to antibody platform as 2025 net loss hits $26M
United States
Key financials
Reported results for Purple Biotech, in USD.
- Market cap
- 1.8M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -47.6
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -27.5M | -26.4M | |
| 0 | -11M | -7.2M | |
| 195.8K | -22.3M | -19.9M | |
| -910K | -22.6M | -21.7M |